Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Diazoxide

FDA-approved product (injectable, injection), marketed as Diazoxide, Hyperstat, Proglycem and 1 more.

Registered studies
39
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Diazoxide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hyperinsulinism
  • Hypertension
  • Hypoglycemia
  • Pancreatic insulinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Thiazide derivatives; Drugs for treatment of hypoglycemia
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA42.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae14.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

39registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Diazoxide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Diazoxide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Regulation of Endogenous Glucose Production by Central KATP Channels

    NCT03540758 · start 2018-08-01

    Registered record
    Registry ID
    NCT03540758
    Conditions
    Diabetes Mellitus; Glucose Metabolism Disorders
    Interventions
    Diazoxide; Nicotinic acid; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2018-08-01
    Completion
    2027-04
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus; Glucose Metabolism Disorders
    InterventionDiazoxide; Nicotinic acid; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide

    NCT03566511 · start 2018-06-12

    Registered record
    Registry ID
    NCT03566511
    Conditions
    Diabetes Mellitus, Type 2; Glucose, High Blood; Glucose Metabolism Disorders (Including Diabetes Mellitus)
    Interventions
    Diazoxide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-06-12
    Completion
    2020-08-01
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2; Glucose, High Blood; Glucose Metabolism Disorders (Including Diabetes Mellitus)
    InterventionDiazoxide; Placebo
    PhasePhase 2
    Registry statusTerminated

  • A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome

    NCT03440814 · start 2018-05-09

    Registered record
    Registry ID
    NCT03440814
    Conditions
    Prader-Willi Syndrome
    Interventions
    DCCR; Placebo for DCCR
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-05-09
    Completion
    2020-05-01
    Enrolment
    127

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrader-Willi Syndrome
    InterventionDCCR; Placebo for DCCR
    PhasePhase 3
    Registry statusCompleted

  • A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)

    NCT02893618 · start 2017-07

    Registered record
    Registry ID
    NCT02893618
    Conditions
    Prader-Willi Syndrome
    Interventions
    Diazoxide choline controlled-release tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2017-07
    Completion
    2017-12
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrader-Willi Syndrome
    InterventionDiazoxide choline controlled-release tablet
    PhasePhase 2
    Registry statusUnknown

  • Pasireotide Treatment for Neuroendocrine Tumor

    NCT02779257 · start 2016-04

    Registered record
    Registry ID
    NCT02779257
    Conditions
    Gastro-enteropancreatic Neuroendocrine Tumor
    Interventions
    Pasireotide; Diazoxide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2016-04
    Completion
    2016-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastro-enteropancreatic Neuroendocrine Tumor
    InterventionPasireotide; Diazoxide
    PhasePhase 4
    Registry statusWithdrawn

  • Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome

    NCT02034071 · start 2014-04

    Registered record
    Registry ID
    NCT02034071
    Conditions
    Prader-Willi Syndrome
    Interventions
    DCCR; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2014-04
    Completion
    2015-05
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrader-Willi Syndrome
    InterventionDCCR; Placebo
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression?

    NCT02049385 · start 2014-01-03

    Registered record
    Registry ID
    NCT02049385
    Conditions
    Depression
    Interventions
    Diazoxide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2014-01-03
    Completion
    2016-07-21
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    InterventionDiazoxide; Placebo
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Use of Diazoxide in Acute Hypoglycaemia

    NCT01488136 · start 2012-01

    Registered record
    Registry ID
    NCT01488136
    Conditions
    Type 1 Diabetes
    Interventions
    Diazoxide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-01
    Completion
    2013-03
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 1 Diabetes
    InterventionDiazoxide; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Open-Label, Single- and Multiple-Dose Pharmacokinetic Study of Diazoxide Choline

    NCT00901823 · start 2011-03

    Registered record
    Registry ID
    NCT00901823
    Conditions
    Hypertriglyceridemia
    Interventions
    Diazoxide choline; Diazoxide choline high dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2011-03
    Completion
    2011-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertriglyceridemia
    InterventionDiazoxide choline; Diazoxide choline high dose
    PhasePhase 1
    Registry statusWithdrawn

  • Diazoxide Choline Controlled-Release Tablet (DCCR) for Very High Triglycerides

    NCT00973271 · start 2011-03

    Registered record
    Registry ID
    NCT00973271
    Conditions
    Hypertriglyceridemia
    Interventions
    290 mg DCCR; 435 mg DCCR; 135 mg fenofibric acid; Placebo; atorvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2011-03
    Completion
    2011-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertriglyceridemia
    Intervention290 mg DCCR; 435 mg DCCR; 135 mg fenofibric acid; Placebo +1 more
    PhasePhase 3
    Registry statusWithdrawn

  • Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia

    NCT01211847 · start 2010-10

    Registered record
    Registry ID
    NCT01211847
    Conditions
    Hypertriglyceridemia; Dyslipidemia
    Interventions
    Diazoxide Choline Controlled-Release Tablet; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-10
    Completion
    2011-12
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertriglyceridemia; Dyslipidemia
    InterventionDiazoxide Choline Controlled-Release Tablet; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetic Study of Diazoxide Choline in Hypertriglyeridemic Subjects

    NCT01211860 · start 2010-10

    Registered record
    Registry ID
    NCT01211860
    Conditions
    Hypertriglyceridmia
    Interventions
    Diazoxide Choline Controlled-Release Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-10
    Completion
    2010-11
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertriglyceridmia
    InterventionDiazoxide Choline Controlled-Release Tablet
    PhasePhase 1
    Registry statusCompleted

  • Diazoxide In the Management Of Hypoglycemic Neonates

    NCT00994149 · start 2009-10

    Registered record
    Registry ID
    NCT00994149
    Conditions
    Infant, Newborn, Diseases; Pregnancy in Diabetics; Infant, Diabetic Mother; Hypoglycemia; Infant, Large for Gestational Age
    Interventions
    Diazoxide; Ora-plus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2009-10
    Completion
    2011-10
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfant, Newborn, Diseases; Pregnancy in Diabetics; Infant, Diabetic Mother; Hypoglycemia +1 more
    InterventionDiazoxide; Ora-plus
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome

    NCT00989781 · start 2009-09

    Registered record
    Registry ID
    NCT00989781
    Conditions
    Polycystic Ovary Syndrome
    Interventions
    3-D Ultrasound; recombinant human chorionic gonadotropin; Recombinant human follicle stimulating hormone; Adrenocorticotropin; Dexamethasone; Glucose
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-09
    Completion
    2013-09
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Ovary Syndrome
    Intervention3-D Ultrasound; recombinant human chorionic gonadotropin; Recombinant human follicle stimulating hormone; Adrenocorticotropin +2 more
    PhaseNot applicable
    Registry statusCompleted

  • DZX Mediated Insulin Suppression in Obese Men

    NCT00631033 · start 2008-07

    Registered record
    Registry ID
    NCT00631033
    Conditions
    Obesity
    Interventions
    Placebo; Diazoxide; Metformin + Diazoxide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-07
    Completion
    2011-12
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity
    InterventionPlacebo; Diazoxide; Metformin + Diazoxide
    PhasePhase 2
    Registry statusCompleted